Obesity
Conditions
Keywords
obesity
Brief summary
A Phase 1 Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity
Detailed description
This study is designed to look at the effect of two doses of PF 06882961 (120 milligram (mg) twice a day (BID) and 200 mg BID) on the levels of one dose of rosuvastatin 10 mg and one dose of midazolam 2 mg, in otherwise healthy, adult participants with obesity. Total duration of study from screening to the telephone visit will be approximately 17 weeks, of which up to 63 days will be inpatient. All subjects take (i) Rosuvastatin alone, Midazolam alone, PF 06882961 alone (120 mg BID), PF 06882961 (120 mg BID) + Rosuvastatin, PF 06882961 (120 mg BID) + Midazolam, PF 06882961 (200 mg BID) alone, PF 06882961 (200 mg BID) + Rosuvastatin, PF 06882961 (200 mg BID)+ Midazolam in the study.
Interventions
Sponsors
Pfizer
Study design
Allocation
NA
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Intervention model description
Crossover
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Body Mass Index (BMI) ≥ 30.0 kg/m2 and not more than 45.4 kg/m2 at Screening. * Stable body weight, defined as \<5 kg change (per participant report) for 90 days before Screening
Exclusion criteria
* Known prior participation in a trial involving PF-06882961. * Known intolerance or hypersensitivity to GLP-1R agonists. * Known hypersensitivity to rosuvastatin or midazolam. * Diagnosis of type 1 or type 2 diabetes mellitus or secondary forms of diabetes at screening. Note: prior diagnoses of gestational diabetes during pregnancy only are eligible if they meet the other eligibility criteria * Any lifetime history of a suicide attempt. * Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing. * Participation in a formal weight reduction program (eg, Weight Watchers) within 90 days prior to Screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area Under the Plasma Concentration-time Profile From Time 0 to Last Quantifiable Concentration (AUClast) of Rosuvastatin in Periods 1, 4 and 7 | At 0 (prior to rosuvastatin dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, and 72 hours post rosuvastatin dose on Day 1 in Periods 1, 4, and 7 | AUClast is area under the plasma concentration-time profile from time 0 to last quantifiable concentration. |
| AUClast of Midazolam in Periods 2, 5 and 8 | At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post midazolam dose on Day 1 in Periods 2, 5, and 8 | AUClast is area under the plasma concentration-time profile from time 0 to last quantifiable concentration. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | From BL (Day 1, the last pre-dose measurement in Period 1) to Follow Up visit (Days 68-71) (approximately up to 71 days) | Single, supine vital signs assessments included systolic blood pressure (BP), diastolic BP and pulse rate. Abnormality in vital signs included: pulse rate \<40 beats per minute (bpm) or \>120bpm; supine diastolic BP \<50 millimeter of mercury (mmHg), increase and decrease in change from BL of \>=20mmHg; supine systolic blood pressure \<90mmHg, increase and decrease in change from BL of \>=30mmHg. |
| Change From Baseline in Body Weight | At BL (Period 1 Day 1), on Period 3 Days 1, 8, 15 and 22, Period 4 Day 1, Period 6 Days 1 and 9, Period 7 Day 1, Period 8 Day 2, and at Follow Up visit (Days 68-71) | Changes from Baseline in body weight of the participants were measured. |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | From first dose of study drug (Day 1) to telephone Follow Up (Days 89-96) (approximately up to 96 days) | An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; or other serious situations such as important medical events. TEAEs were events between first dose of study drug and up to follow-up visit that were absent before treatment or that worsened after treatment. AEs presented below were TEAEs. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE. |
| Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) | At BL (Period 1 Day 1), on Period 3 Days 1, 8, 15, and 22, Period 4 Day 1, Period 6 Days 1, 9, and 16, Period 8 Day 2, at Follow Up visit (Days 68-71) and Early Termination | The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of yes on actual attempt), 3: preparatory acts towards imminent suicidal behavior (yes on aborted attempt, interrupted attempt, preparatory acts/behavior), 4: suicidal ideation (yes on wish to be dead, non-specific active suicidal thoughts), 7: self-injurious behavior, no suicidal intent (yes on has participant engaged in non-suicidal self-injurious behavior). In this outcome, number of participants with positive response (response of yes) to suicidal behavior, ideation, or any self-injurious behavior were reported. |
| Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | At BL (Period 1 Day 1), on Period 3 Days 1, 8, 15, and 22, Period 4 Day 1, Period 6 Days 1, 9, and 16, Period 8 Day 2, at Follow Up visit (Days 68-71) and Early Termination | The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The questions included little interest/pleasure in things, feeling down depressed or hopeless, trouble falling or staying asleep, feeling tired or little energy, poor appetite or overeating, feeling bad about yourself, trouble concentrating on things, moving slowly or fidgety/restless and thoughts you be better off dead. Each item was scored on scale of not at all, several days, more than half the days to nearly every day. Total score range: 0-27 (each item with scale from 0 \[not at all\] to 3 \[nearly every day\]. Higher score=greater severity). |
| Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | From BL (Day 1, the last pre-dose measurement in Period 1) to Follow Up visit (Days 68-71) (approximately up to 71 days) | ECG assessments included pulse rate (PR), QT, QTcF intervals and QRS complex. ECG abnormalities criteria included: PR interval value \>= 300msec, or BL \>200msec and \>=25% increase from BL, or BL \<=200msec and \>=50% increase from BL; QRS interval value \>= 140msec, or percent change from BL \>=50%; QTcF value \>400 and \<=480msec, or \>480 and \<=500 msec, or \>500msec, or change from BL\>30 and \<=60msec, or change from BL \>60msec. |
| Number of Participants With Laboratory Abnormalities (Without Regard to Baseline [BL] Abnormality) | From BL (Day 1, the last pre-dose measurement in Period 1) to Follow Up visit (Days 68-71) (approximately up to 71 days) | Safety laboratory assessments included clinical chemistry, hematology, urinalysis, and other tests. Abnormality was determined at the investigator's discretion. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| All Participants Participants underwent Period 1 to 8 and received study interventions as follows: Period 1: rosuvastatin 10mg once daily (QD) on Day 1; Period 2: midazolam 2mg QD on Day 1; Period 3: PF-06882961 (danuglipron) 10mg twice a day (BID) on Days 1-4, 20mg BID on Days 5-8, 40mg BID on Days 9-12, 60mg BID on Days 13-16, 80mg BID on Days 17-20, 100mg BID on Days 21-24, and 120mg BID on Days 25-28; Period 4: PF-06882961 120mg BID on Days 1-4 + rosuvastatin 10mg QD on Day 1; Period 5: PF-06882961 120mg BID + midazolam 2mg QD on Day 1; Period 6: PF-06882961 140mg BID on Days 1-4, 160mg BID on Days 5-8, 180mg BID on Days 9-12, and 200mg BID on Days 13-16; Period 7: PF-06882961 200mg BID on Days 1-4 + rosuvastatin 10mg QD on Day 1; Period 8: PF-06882961 200mg BID + midazolam 2mg QD on Day 1. | 16 |
| Total | 16 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Period 3 (29 Days) | Adverse Event | 1 |
| Period 3 (29 Days) | Physician decision due to inappropriate behavior and noncompliance | 1 |
| Period 8 (2 Days) | Adverse Event | 1 |
Baseline characteristics
| Characteristic | All Participants |
|---|---|
| Age, Continuous | 49.0 Years STANDARD_DEVIATION 11.34 |
| Age, Customized 18-44 Years | 5 Participants |
| Age, Customized <18 Years | 0 Participants |
| Age, Customized 45-65 Years | 11 Participants |
| Race/Ethnicity, Customized American Indian or Alaska Native | 1 Participants |
| Race/Ethnicity, Customized Black or African American | 3 Participants |
| Race/Ethnicity, Customized White | 12 Participants |
| Sex: Female, Male Female | 8 Participants |
| Sex: Female, Male Male | 8 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 16 | 0 / 16 | 0 / 16 | 0 / 14 | 0 / 14 | 0 / 14 | 0 / 14 | 0 / 14 |
| other Total, other adverse events | 0 / 16 | 2 / 16 | 13 / 16 | 6 / 14 | 5 / 14 | 11 / 14 | 7 / 14 | 8 / 14 |
| serious Total, serious adverse events | 0 / 16 | 0 / 16 | 0 / 16 | 0 / 14 | 0 / 14 | 0 / 14 | 0 / 14 | 1 / 14 |
Outcome results
Primary
Area Under the Plasma Concentration-time Profile From Time 0 to Last Quantifiable Concentration (AUClast) of Rosuvastatin in Periods 1, 4 and 7
AUClast is area under the plasma concentration-time profile from time 0 to last quantifiable concentration.
Time frame: At 0 (prior to rosuvastatin dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, and 72 hours post rosuvastatin dose on Day 1 in Periods 1, 4, and 7
Population: The PK parameter analysis population was defined as all participants who received at least 1 dose of rosuvastatin and had at least 1 of the PK parameters of interest calculated.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Rosuvastatin 10mg (Period 1) | Area Under the Plasma Concentration-time Profile From Time 0 to Last Quantifiable Concentration (AUClast) of Rosuvastatin in Periods 1, 4 and 7 | 35.17 nanogram*hour per milliliter (ng*hr/mL) | Geometric Coefficient of Variation 43 |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Area Under the Plasma Concentration-time Profile From Time 0 to Last Quantifiable Concentration (AUClast) of Rosuvastatin in Periods 1, 4 and 7 | 72.15 nanogram*hour per milliliter (ng*hr/mL) | Geometric Coefficient of Variation 50 |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Area Under the Plasma Concentration-time Profile From Time 0 to Last Quantifiable Concentration (AUClast) of Rosuvastatin in Periods 1, 4 and 7 | 100.90 nanogram*hour per milliliter (ng*hr/mL) | Geometric Coefficient of Variation 40 |
Comparison: Comparison for AUClast (PF-06882961 120mg BID + rosuvastatin 10mg \[Period 4\] vs Rosuvastatin 10mg \[Period 1\])90% CI: [167.14, 246.41]Mixed Models Analysis
Comparison: Comparison for AUClast (PF-06882961 200mg BID + rosuvastatin 10mg \[Period 7\] vs Rosuvastatin 10mg \[Period 1\])90% CI: [233.68, 344.51]Mixed Models Analysis
Primary
AUClast of Midazolam in Periods 2, 5 and 8
AUClast is area under the plasma concentration-time profile from time 0 to last quantifiable concentration.
Time frame: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post midazolam dose on Day 1 in Periods 2, 5, and 8
Population: The PK parameter analysis population was defined as all participants who received at least 1 dose of rosuvastatin and had at least 1 of the PK parameters of interest calculated.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Rosuvastatin 10mg (Period 1) | AUClast of Midazolam in Periods 2, 5 and 8 | 39.24 nanogram*hour per milliliter (ng*hr/mL) | Geometric Coefficient of Variation 27 |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | AUClast of Midazolam in Periods 2, 5 and 8 | 19.98 nanogram*hour per milliliter (ng*hr/mL) | Geometric Coefficient of Variation 49 |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | AUClast of Midazolam in Periods 2, 5 and 8 | 20.21 nanogram*hour per milliliter (ng*hr/mL) | Geometric Coefficient of Variation 48 |
Comparison: Comparison for AUClast (PF-06882961 120mg BID + midazolam 2mg \[Period 5\] vs Midazolam 2mg \[Period 2\])90% CI: [42.27, 60.5]Mixed Models Analysis
Comparison: Comparison for AUClast (PF-06882961 200mg BID + midazolam 2mg \[Period 8\] vs Midazolam 2mg \[Period 2\])90% CI: [42.06, 60.78]Mixed Models Analysis
Secondary
Change From Baseline in Body Weight
Changes from Baseline in body weight of the participants were measured.
Time frame: At BL (Period 1 Day 1), on Period 3 Days 1, 8, 15 and 22, Period 4 Day 1, Period 6 Days 1 and 9, Period 7 Day 1, Period 8 Day 2, and at Follow Up visit (Days 68-71)
Population: The analysis set included all participants assigned to study intervention and who took at least 1 dose of study intervention. Participants with evaluable body weight data were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rosuvastatin 10mg (Period 1) | Change From Baseline in Body Weight | Period 3 Day 1 / PF-06882961 titration up to 120 mg BID | -1.5 kilogram (kg) | Standard Deviation 0.82 |
| Rosuvastatin 10mg (Period 1) | Change From Baseline in Body Weight | Period 3 Day 8 / PF-06882961 titration up to 120 mg BID | -1.9 kilogram (kg) | Standard Deviation 1.56 |
| Rosuvastatin 10mg (Period 1) | Change From Baseline in Body Weight | Period 3 Day 15 / PF-06882961 titration up to 120 mg BID | -3.3 kilogram (kg) | Standard Deviation 1.24 |
| Rosuvastatin 10mg (Period 1) | Change From Baseline in Body Weight | Period 3 Day 22 / PF-06882961 titration up to 120 mg BID | -4.3 kilogram (kg) | Standard Deviation 1.69 |
| Rosuvastatin 10mg (Period 1) | Change From Baseline in Body Weight | Period 4 Day 1 / PF-06882961 120 mg BID + rosuvastatin 10 mg | -5.2 kilogram (kg) | Standard Deviation 1.87 |
| Rosuvastatin 10mg (Period 1) | Change From Baseline in Body Weight | Period 6 Day 1 / PF-06882961 titration up to 200 mg BID | -6.1 kilogram (kg) | Standard Deviation 2.18 |
| Rosuvastatin 10mg (Period 1) | Change From Baseline in Body Weight | Period 6 Day 9 / PF-06882961 titration up to 200 mg BID | -7.5 kilogram (kg) | Standard Deviation 2.49 |
| Rosuvastatin 10mg (Period 1) | Change From Baseline in Body Weight | Period 7 Day 1 / PF-06882961 200 mg BID + rosuvastatin 10 mg | -9.1 kilogram (kg) | Standard Deviation 2.76 |
| Rosuvastatin 10mg (Period 1) | Change From Baseline in Body Weight | Period 8 Day 2 / PF-06882961 200 mg BID + midazolam 2 mg | -9.9 kilogram (kg) | Standard Deviation 3.15 |
| Rosuvastatin 10mg (Period 1) | Change From Baseline in Body Weight | Follow up | -5.7 kilogram (kg) | Standard Deviation 3.05 |
Secondary
Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9)
The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The questions included little interest/pleasure in things, feeling down depressed or hopeless, trouble falling or staying asleep, feeling tired or little energy, poor appetite or overeating, feeling bad about yourself, trouble concentrating on things, moving slowly or fidgety/restless and thoughts you be better off dead. Each item was scored on scale of not at all, several days, more than half the days to nearly every day. Total score range: 0-27 (each item with scale from 0 \[not at all\] to 3 \[nearly every day\]. Higher score=greater severity).
Time frame: At BL (Period 1 Day 1), on Period 3 Days 1, 8, 15, and 22, Period 4 Day 1, Period 6 Days 1, 9, and 16, Period 8 Day 2, at Follow Up visit (Days 68-71) and Early Termination
Population: The analysis set included all participants assigned to study intervention and who took at least 1 dose of study intervention. Participants with evaluable PHQ-9 results were analyzed.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Feeling Tired or Little Energy | Several Days | 3 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Trouble Falling or Staying Asleep | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Feeling Tired or Little Energy | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Feeling Tired or Little Energy | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Poor Appetite or Overeating | Not At All | 12 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Poor Appetite or Overeating | Several Days | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Poor Appetite or Overeating | More Than Half The Days | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Feeling Bad About Yourself | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Feeling Bad About Yourself | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Trouble Concentrating on Things | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Trouble Concentrating on Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Moving Slowly or Fidgety/Restless | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Thoughts You Be Better Off Dead | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Little Interest/Pleasure in Things | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Feeling Down Depressed or Hopeless | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Trouble Falling or Staying Asleep | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Feeling Tired or Little Energy | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Feeling Tired or Little Energy | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Poor Appetite or Overeating | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Poor Appetite or Overeating | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Feeling Bad About Yourself | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Feeling Bad About Yourself | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Trouble Concentrating on Things | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Trouble Concentrating on Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Moving Slowly or Fidgety/Restless | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Thoughts You Be Better Off Dead | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Follow Up Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Little Interest/Pleasure in Things | Not At All | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Feeling Down Depressed or Hopeless | Not At All | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Trouble Falling or Staying Asleep | Not At All | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Feeling Tired or Little Energy | Not At All | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Feeling Tired or Little Energy | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Poor Appetite or Overeating | Not At All | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Poor Appetite or Overeating | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Feeling Bad About Yourself | Not At All | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Feeling Bad About Yourself | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Trouble Concentrating on Things | Not At All | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Trouble Concentrating on Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Moving Slowly or Fidgety/Restless | Not At All | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Thoughts You Be Better Off Dead | Not At All | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | ET Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Feeling Tired or Little Energy | Not At All | 11 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Poor Appetite or Overeating | Not At All | 12 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Poor Appetite or Overeating | Several Days | 2 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Feeling Bad About Yourself | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Feeling Bad About Yourself | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Trouble Concentrating on Things | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Trouble Concentrating on Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Moving Slowly or Fidgety/Restless | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Thoughts You Be Better Off Dead | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Little Interest/Pleasure in Things | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Feeling Down Depressed or Hopeless | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Trouble Falling or Staying Asleep | Not At All | 12 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Trouble Falling or Staying Asleep | Several Days | 2 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Feeling Tired or Little Energy | Not At All | 13 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Feeling Tired or Little Energy | Several Days | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Poor Appetite or Overeating | Not At All | 11 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Poor Appetite or Overeating | Several Days | 3 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Feeling Bad About Yourself | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Feeling Bad About Yourself | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Trouble Concentrating on Things | Not At All | 13 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Trouble Concentrating on Things | Several Days | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Moving Slowly or Fidgety/Restless | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Thoughts You Be Better Off Dead | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Little Interest/Pleasure in Things | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Feeling Down Depressed or Hopeless | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Trouble Falling or Staying Asleep | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Feeling Tired or Little Energy | Not At All | 13 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Feeling Tired or Little Energy | Several Days | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Poor Appetite or Overeating | Not At All | 12 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Poor Appetite or Overeating | Several Days | 2 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Feeling Bad About Yourself | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Feeling Bad About Yourself | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Trouble Concentrating on Things | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Trouble Concentrating on Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Moving Slowly or Fidgety/Restless | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Thoughts You Be Better Off Dead | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Little Interest/Pleasure in Things | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Feeling Down Depressed or Hopeless | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Trouble Falling or Staying Asleep | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Feeling Tired or Little Energy | Not At All | 11 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Feeling Tired or Little Energy | Several Days | 3 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Poor Appetite or Overeating | Not At All | 13 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Poor Appetite or Overeating | Several Days | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Feeling Bad About Yourself | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Feeling Bad About Yourself | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Trouble Concentrating on Things | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Trouble Concentrating on Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Moving Slowly or Fidgety/Restless | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Thoughts You Be Better Off Dead | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Little Interest/Pleasure in Things | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Feeling Down Depressed or Hopeless | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Trouble Falling or Staying Asleep | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Trouble Falling or Staying Asleep | Several Days | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Little Interest/Pleasure in Things | Not At All | 16 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Feeling Down Depressed or Hopeless | Not At All | 16 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Trouble Falling or Staying Asleep | Not At All | 16 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Feeling Tired or Little Energy | Not At All | 16 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Feeling Tired or Little Energy | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Poor Appetite or Overeating | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Poor Appetite or Overeating | Several Days | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Feeling Bad About Yourself | Not At All | 16 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Feeling Bad About Yourself | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Trouble Concentrating on Things | Not At All | 16 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Trouble Concentrating on Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Moving Slowly or Fidgety/Restless | Not At All | 16 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Poor Appetite or Overeating | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Feeling Bad About Yourself | Not At All | 16 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Feeling Bad About Yourself | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Trouble Concentrating on Things | Not At All | 16 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Trouble Concentrating on Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Moving Slowly or Fidgety/Restless | Not At All | 16 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Thoughts You Be Better Off Dead | Not At All | 16 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Little Interest/Pleasure in Things | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Feeling Down Depressed or Hopeless | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Trouble Falling or Staying Asleep | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Feeling Tired or Little Energy | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Feeling Tired or Little Energy | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Poor Appetite or Overeating | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Poor Appetite or Overeating | Several Days | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Feeling Bad About Yourself | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Feeling Bad About Yourself | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Trouble Concentrating on Things | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Trouble Concentrating on Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Moving Slowly or Fidgety/Restless | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Thoughts You Be Better Off Dead | Not At All | 16 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Thoughts You Be Better Off Dead | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Little Interest/Pleasure in Things | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Little Interest/Pleasure in Things | Several Days | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Feeling Down Depressed or Hopeless | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Trouble Falling or Staying Asleep | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Trouble Falling or Staying Asleep | Several Days | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Feeling Tired or Little Energy | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Feeling Tired or Little Energy | Several Days | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Poor Appetite or Overeating | Not At All | 13 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Poor Appetite or Overeating | Several Days | 2 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Feeling Bad About Yourself | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Feeling Bad About Yourself | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Trouble Concentrating on Things | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Trouble Concentrating on Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Moving Slowly or Fidgety/Restless | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Thoughts You Be Better Off Dead | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Little Interest/Pleasure in Things | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Feeling Down Depressed or Hopeless | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Trouble Falling or Staying Asleep | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Feeling Tired or Little Energy | Not At All | 13 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Feeling Tired or Little Energy | Several Days | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Poor Appetite or Overeating | Not At All | 11 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Poor Appetite or Overeating | Several Days | 3 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Poor Appetite or Overeating | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Poor Appetite or Overeating | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Feeling Bad About Yourself | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Feeling Bad About Yourself | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Feeling Bad About Yourself | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Feeling Bad About Yourself | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Trouble Concentrating on Things | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | BL Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1/PF-06882961 titration up to 120mg BID Little Interest/Pleasure in Things | Not At All | 16 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1/PF-06882961 titration up to 120mg BID Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Trouble Concentrating on Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Trouble Concentrating on Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Trouble Concentrating on Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Moving Slowly or Fidgety/Restless | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Moving Slowly or Fidgety/Restless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Moving Slowly or Fidgety/Restless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Moving Slowly or Fidgety/Restless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Thoughts You Be Better Off Dead | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Thoughts You Be Better Off Dead | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1/PF-06882961 titration up to 120mg BID Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1/PF-06882961 titration up to 120mg BID Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Feeling Down Depressed or Hopeless | Not At All | 16 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Feeling Down Depressed or Hopeless | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Trouble Falling or Staying Asleep | Not At All | 16 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Trouble Falling or Staying Asleep | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Trouble Falling or Staying Asleep | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Trouble Falling or Staying Asleep | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Feeling Tired or Little Energy | Not At All | 15 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Feeling Tired or Little Energy | Several Days | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Feeling Tired or Little Energy | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Feeling Tired or Little Energy | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID Poor Appetite or Overeating | Not At All | 16 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Thoughts You Be Better Off Dead | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID Thoughts You Be Better Off Dead | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Little Interest/Pleasure in Things | Not At All | 14 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Little Interest/Pleasure in Things | Several Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Little Interest/Pleasure in Things | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Little Interest/Pleasure in Things | Nearly Every Day | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Feeling Down Depressed or Hopeless | Not At All | 13 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Feeling Down Depressed or Hopeless | Several Days | 1 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Feeling Down Depressed or Hopeless | More Than Half The Days | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg Feeling Down Depressed or Hopeless | Nearly Every Day | 0 Participants |
Secondary
Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria
ECG assessments included pulse rate (PR), QT, QTcF intervals and QRS complex. ECG abnormalities criteria included: PR interval value \>= 300msec, or BL \>200msec and \>=25% increase from BL, or BL \<=200msec and \>=50% increase from BL; QRS interval value \>= 140msec, or percent change from BL \>=50%; QTcF value \>400 and \<=480msec, or \>480 and \<=500 msec, or \>500msec, or change from BL\>30 and \<=60msec, or change from BL \>60msec.
Time frame: From BL (Day 1, the last pre-dose measurement in Period 1) to Follow Up visit (Days 68-71) (approximately up to 71 days)
Population: The analysis set included all participants assigned to study intervention and who took at least 1 dose of study intervention. Participants with evaluable ECG data were analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Rosuvastatin 10mg (Period 1) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF change >30 and <=60 msec | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval %change >=50% | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >500 msec | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >480 and <=500 msec | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF change >60 msec | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval %change >=25/50% (BL >200 msec and >=25% increase or BL <=200 msec and >=50% increase) | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >450 and <=480 msec | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval value>=140 msec | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval value>=300 msec | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval value>=140 msec | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval value>=300 msec | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval %change >=50% | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF change >30 and <=60 msec | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >450 and <=480 msec | 1 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF change >60 msec | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval %change >=25/50% (BL >200 msec and >=25% increase or BL <=200 msec and >=50% increase) | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >480 and <=500 msec | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >500 msec | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval value>=140 msec | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >480 and <=500 msec | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF change >60 msec | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval %change >=25/50% (BL >200 msec and >=25% increase or BL <=200 msec and >=50% increase) | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval value>=300 msec | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF change >30 and <=60 msec | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval %change >=50% | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >500 msec | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >450 and <=480 msec | 2 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval %change >=50% | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval value>=140 msec | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >450 and <=480 msec | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF change >30 and <=60 msec | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval %change >=25/50% (BL >200 msec and >=25% increase or BL <=200 msec and >=50% increase) | 1 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF change >60 msec | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >500 msec | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval value>=300 msec | 1 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >480 and <=500 msec | 0 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >450 and <=480 msec | 0 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval value>=300 msec | 1 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval %change >=25/50% (BL >200 msec and >=25% increase or BL <=200 msec and >=50% increase) | 1 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval value>=140 msec | 0 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval %change >=50% | 0 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >480 and <=500 msec | 0 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >500 msec | 0 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF change >30 and <=60 msec | 0 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF change >60 msec | 0 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval %change >=25/50% (BL >200 msec and >=25% increase or BL <=200 msec and >=50% increase) | 0 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval value>=300 msec | 0 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >500 msec | 0 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval value>=140 msec | 0 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval %change >=50% | 0 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF change >60 msec | 0 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >450 and <=480 msec | 1 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF change >30 and <=60 msec | 0 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >480 and <=500 msec | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF change >30 and <=60 msec | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval value>=300 msec | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >450 and <=480 msec | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >500 msec | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval %change >=50% | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval value>=140 msec | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval %change >=25/50% (BL >200 msec and >=25% increase or BL <=200 msec and >=50% increase) | 1 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF change >60 msec | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >480 and <=500 msec | 0 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF change >60 msec | 0 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >480 and <=500 msec | 0 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval %change >=50% | 0 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QRS interval value>=140 msec | 0 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >500 msec | 0 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval %change >=25/50% (BL >200 msec and >=25% increase or BL <=200 msec and >=50% increase) | 0 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF change >30 and <=60 msec | 0 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | PR interval value>=300 msec | 0 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria | QTcF value >450 and <=480 msec | 0 Participants |
Secondary
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline [BL] Abnormality)
Safety laboratory assessments included clinical chemistry, hematology, urinalysis, and other tests. Abnormality was determined at the investigator's discretion.
Time frame: From BL (Day 1, the last pre-dose measurement in Period 1) to Follow Up visit (Days 68-71) (approximately up to 71 days)
Population: The analysis set included all participants assigned to study intervention and who took at least 1 dose of study intervention. Participants with evaluable laboratory values were analyzed.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Rosuvastatin 10mg (Period 1) | Number of Participants With Laboratory Abnormalities (Without Regard to Baseline [BL] Abnormality) | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Laboratory Abnormalities (Without Regard to Baseline [BL] Abnormality) | 3 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Laboratory Abnormalities (Without Regard to Baseline [BL] Abnormality) | 5 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Laboratory Abnormalities (Without Regard to Baseline [BL] Abnormality) | 2 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Laboratory Abnormalities (Without Regard to Baseline [BL] Abnormality) | 3 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Laboratory Abnormalities (Without Regard to Baseline [BL] Abnormality) | 5 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Laboratory Abnormalities (Without Regard to Baseline [BL] Abnormality) | 0 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Laboratory Abnormalities (Without Regard to Baseline [BL] Abnormality) | 9 Participants |
Secondary
Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of yes on actual attempt), 3: preparatory acts towards imminent suicidal behavior (yes on aborted attempt, interrupted attempt, preparatory acts/behavior), 4: suicidal ideation (yes on wish to be dead, non-specific active suicidal thoughts), 7: self-injurious behavior, no suicidal intent (yes on has participant engaged in non-suicidal self-injurious behavior). In this outcome, number of participants with positive response (response of yes) to suicidal behavior, ideation, or any self-injurious behavior were reported.
Time frame: At BL (Period 1 Day 1), on Period 3 Days 1, 8, 15, and 22, Period 4 Day 1, Period 6 Days 1, 9, and 16, Period 8 Day 2, at Follow Up visit (Days 68-71) and Early Termination
Population: The analysis set included all participants assigned to study intervention and who took at least 1 dose of study intervention. Participants with evaluable C-SSRS results were analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Rosuvastatin 10mg (Period 1) | Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) | BL | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) | BL (Past 12 months) | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 3 Day 1 / PF-06882961 titration up to 120mg BID (Since last visit) | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 3 Day 8 / PF-06882961 titration up to 120mg BID (Since last visit) | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 3 Day 15 / PF-06882961 titration up to 120mg BID (Since last visit) | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 3 Day 22 / PF-06882961 titration up to 120mg BID (Since last visit) | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 4 Day 1 / PF-06882961 120mg BID + rosuvastatin 10mg (Since last visit) | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 6 Day 1 / PF-06882961 titration up to 200mg BID (Since last visit) | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 6 Day 9 / PF-06882961 titration up to 200mg BID (Since last visit) | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 6 Day 16 / PF-06882961 titration up to 200mg BID (Since last visit) | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) | Period 8 Day 2 / PF-06882961 200mg BID + midazolam 2mg (Since last visit) | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) | Follow Up (Since last visit) | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) | Early Termination (ET) (Since last visit) | 0 Participants |
Secondary
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; or other serious situations such as important medical events. TEAEs were events between first dose of study drug and up to follow-up visit that were absent before treatment or that worsened after treatment. AEs presented below were TEAEs. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.
Time frame: From first dose of study drug (Day 1) to telephone Follow Up (Days 89-96) (approximately up to 96 days)
Population: The safety analysis set included all participants assigned to study intervention and who took at least 1 dose of study intervention.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Rosuvastatin 10mg (Period 1) | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | All-causality TEAEs | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Treatment-related TEAEs | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | All-causality TEAEs | 2 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Treatment-related TEAEs | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | All-causality TEAEs | 13 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Treatment-related TEAEs | 11 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | All-causality TEAEs | 6 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Treatment-related TEAEs | 5 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | All-causality TEAEs | 5 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Treatment-related TEAEs | 5 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | All-causality TEAEs | 11 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Treatment-related TEAEs | 10 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Treatment-related TEAEs | 3 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | All-causality TEAEs | 7 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | All-causality TEAEs | 8 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Treatment-related TEAEs | 7 Participants |
Secondary
Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria
Single, supine vital signs assessments included systolic blood pressure (BP), diastolic BP and pulse rate. Abnormality in vital signs included: pulse rate \<40 beats per minute (bpm) or \>120bpm; supine diastolic BP \<50 millimeter of mercury (mmHg), increase and decrease in change from BL of \>=20mmHg; supine systolic blood pressure \<90mmHg, increase and decrease in change from BL of \>=30mmHg.
Time frame: From BL (Day 1, the last pre-dose measurement in Period 1) to Follow Up visit (Days 68-71) (approximately up to 71 days)
Population: The analysis set included all participants assigned to study intervention and who took at least 1 dose of study intervention. Participants with evaluable vital signs data were analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Rosuvastatin 10mg (Period 1) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP value <50mmHg | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Pulse rate value >120bpm | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Pulse rate value <40bpm | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP change >=20mmHg increase | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP change >=20mmHg decrease | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP value <90mmHg | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP change >=30mmHg increase | 0 Participants |
| Rosuvastatin 10mg (Period 1) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP change >=30mmHg decrease | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP change >=20mmHg decrease | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP value <50mmHg | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP value <90mmHg | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP change >=30mmHg increase | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Pulse rate value <40bpm | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP change >=20mmHg increase | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Pulse rate value >120bpm | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP change >=30mmHg decrease | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP change >=30mmHg increase | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP change >=20mmHg decrease | 1 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP change >=30mmHg decrease | 2 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP value <50mmHg | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP value <90mmHg | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP change >=20mmHg increase | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Pulse rate value <40bpm | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Pulse rate value >120bpm | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP change >=30mmHg decrease | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Pulse rate value >120bpm | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Pulse rate value <40bpm | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP change >=20mmHg increase | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP value <50mmHg | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP change >=20mmHg decrease | 0 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP value <90mmHg | 1 Participants |
| PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP change >=30mmHg increase | 0 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP change >=20mmHg increase | 0 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP change >=30mmHg increase | 0 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP value <50mmHg | 0 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Pulse rate value <40bpm | 0 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP change >=30mmHg decrease | 2 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP change >=20mmHg decrease | 3 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP value <90mmHg | 0 Participants |
| PF-06882961 120mg BID + Midazolam 2mg (Period 5) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Pulse rate value >120bpm | 0 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP change >=30mmHg decrease | 3 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Pulse rate value >120bpm | 0 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP value <50mmHg | 0 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Pulse rate value <40bpm | 0 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP change >=30mmHg increase | 0 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP value <90mmHg | 1 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP change >=20mmHg decrease | 3 Participants |
| PF-06882961 Titration up to 200mg BID (Period 6) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP change >=20mmHg increase | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP value <50mmHg | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Pulse rate value >120bpm | 1 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP change >=20mmHg increase | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP change >=20mmHg decrease | 1 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP value <90mmHg | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP change >=30mmHg decrease | 2 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP change >=30mmHg increase | 0 Participants |
| PF-06882961 200mg BID + Rosuvastatin 10mg (Period 7) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Pulse rate value <40bpm | 0 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP change >=30mmHg decrease | 0 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP value <90mmHg | 0 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP change >=20mmHg decrease | 1 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP change >=20mmHg increase | 0 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine diastolic BP value <50mmHg | 1 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Pulse rate value >120bpm | 0 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Pulse rate value <40bpm | 0 Participants |
| PF-06882961 200mg BID + Midazolam 2mg (Period 8) | Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria | Supine systolic BP change >=30mmHg increase | 0 Participants |